Across TCGA pan-cancer cohorts, PAFAH1B1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PAFAH1B1 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher PAFAH1B1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PAFAH1B1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
ESCA and UCEC are the cancer types where PAFAH1B1 Mutation most reproducibly stratifies survival.